

Amerigo Scientific Releases Transglutaminase Inhibitors to Unlock Their Therapeutic Potential in Diseases

Amerigo Scientific announces its transglutaminase inhibitors, designed to advance research into their therapeutic applications across a range of diseases.

NEW YORK, NY, UNITED STATES, February 28, 2025 /EINPresswire.com/ -- Amerigo Scientific releases [transglutaminase inhibitors](#) designed to advance research into their therapeutic applications across a range of diseases. These transglutaminase inhibitors seek to enable ground-breaking findings in a number of domains, such as autoimmune illnesses, neurological diseases, and cancer research.

“We recognize the urgent need for effective research tools that can shed light on the complex roles of transglutaminases in disease,” said the Chief Scientific Officer at Amerigo Scientific. “Our transglutaminase inhibitors represent a significant step forward in providing researchers the resources they need to uncover novel pathways and potential treatments.”

A family of enzymes known as transglutaminases (TG) is essential for both cellular activity and protein crosslinking. Although these enzymes are necessary for regular physiological functions, studies find several diseases have been linked to their dysregulation. Amerigo Scientific’s transglutaminase inhibitors can serve as pivotal tools for researchers aiming to delineate TG-related mechanisms and explore therapeutic avenues for diseases associated with aberrant transglutaminase activity.

The innovative inhibitors from Amerigo Scientific are characterized by their high specificity and potency. They have undergone rigorous testing to ensure reliability and effectiveness in diverse experimental models, making them indispensable for laboratories focused on advancing our understanding of transglutaminase-related diseases.

In addition to transglutaminase inhibitors, Amerigo Scientific also offers other [ubiquitin proteasome products](#) such as ubiquitin / ubiquitin-like proteins and mutants, ubiquitin chains, ubiquitination and deubiquitination enzymes, activators, and subunits. These products are designed to facilitate advanced research in protein degradation pathways, cellular regulation, and the development of therapeutics targeting various diseases related to protein misfolding and aggregation. Furthermore, Amerigo Scientific's online shop also includes high-quality reagents for studying the mechanisms of ubiquitin signaling, allowing researchers to explore

novel insights into cellular processes such as cell cycle regulation, DNA repair, and immune responses. Whether researchers are conducting basic research or developing innovative biopharmaceuticals, Amerigo Scientific is committed to providing the tools necessary to drive their discoveries forward.

About Amerigo Scientific

Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation to all companies and institutions in the branch of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers' questions or concerns and are always ready to provide individualized customer service of high standards.

Phoebe Davis

Amerigo Scientific

contact@amerigoscientific.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/789883138>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.